Skip to main content

In Brief This Week: Enzo Biochem and Roche Diagnostics

NEW YORK (360Dx) – Enzo Biochem said this week that it has entered an agreement to purchase a nearly 36,000-square-foot commercial facility in Farmingdale, New York, that it anticipates will enhance its ability to produce and distribute a growing portfolio of molecular, immunohistochemistry, immunoassay, and immune-oncology products and services.

The building, adjacent to the company's Long Island campus, expands the infrastructure needed to produce and distribute its expanding diagnostic platform products and related services, including automation-compatible reagent systems and associated products for sample collection and processing through analysis. The new facility also provides more space for production of its development-stage clinical candidates, including its sphingosine kinase 1 inhibitor, SK1-I, which is being investigated for potential applications in oncology and autoimmune diseases.

In connection with the acquisition of the new facility, the Town of Babylon Industrial Development Agency has committed to providing multi-year tax abatements and additional incentives.


Roche Diagnostics said this week that it is collaborating with the University of Indianapolis to generate a custom talent pipeline of biomedical equipment technicians through the newly created Roche Academy. The partnership was co-developed with Ascend Indiana, a central Indiana corporate partnership initiative.

As Roche's customer base continues to grow, the demand for quality and properly trained biomedical equipment technicians continues to increase, the firm said. It noted that these technicians are critical to its operations, as they maintain critical lab equipment and provide customer service across its geographic service regions.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.